Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). - Wikidata - wikimedia - TriplyDB

Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study).

Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study).

http://www.wikidata.org/entity/Q34092442

about

Benefit-risk assessment of golimumab in the treatment of refractory ulcerative colitis Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists Advances in the treatment of polyarticular juvenile idiopathic arthritis New targets in psoriatic arthritis Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes Emerging drugs for the treatment of axial and peripheral spondyloarthritis.Psoriatic arthritis: latest treatments and their place in therapy.Novel systemic therapies for the treatment of psoriasis.Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis.Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis.Tumor necrosis factor inhibitors in psoriatic arthritis.Golimumab: A Review in Inflammatory Arthritis.The safety of ustekinumab for the treatment of psoriatic arthritis.Current challenges and emerging drug delivery strategies for the treatment of psoriasis.Treatment of psoriatic arthritis with traditional DMARD's and novel therapies: approaches and recommendations.Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study.Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1.Consensus on the management of patients with psoriatic arthritis in a dermatology setting.A review on golimumab in the treatment of psoriatic arthritis.Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.The role of golimumab in inflammatory arthritis. A review of the evidence

P2860

Q26764801-B342350F-85A0-4FF5-B0F4-4506BFF00AEA Q26764867-56A98BE8-EFB7-4B40-BEA4-C1EAB2EACDAC Q26999078-8AD68C39-1AED-491E-8CFF-BE33D270692C Q27001017-A1B17F35-82E4-4857-BF6F-CA46B491C48C Q28069592-7D263A4C-6AD8-48A4-9B10-F67EF94A3BF6 Q33563272-A47B8491-DAB4-4862-89D1-0D24D7C224EC Q33916770-4D700FD7-FCD2-4040-B223-86D9F53BC678 Q38313266-A968AEAA-8FE4-4DD3-90E3-CB26CC7500A2 Q38542095-1FF270AF-CA61-42A1-867F-7BC3175AB679 Q38628193-267A913D-8FF1-4CD8-8EDC-C52FE12DECAE Q38630548-656BF50F-3D91-4733-A9D0-A7C1B1C7A269 Q38667430-7C2C04D1-509B-4F89-82A6-FCB38676DE33 Q38685543-1E921461-63B2-4891-8D65-F528DBFE1AC6 Q38771878-69CA5413-8BFA-4C69-B200-2934674B1BD8 Q38820480-2FF2018C-2264-4AA4-A134-0392859AD163 Q38831055-3C79036B-2006-4C79-A53B-7DC3DBB74BF3 Q39003610-9E4F146D-A0EA-4A39-877C-3E6290AE3209 Q39371316-F4418939-5E63-4BF6-B0DD-667F6A0F0722 Q41478116-0B64CAB1-8528-412F-9155-70DB71F297CA Q47148249-5B67A72B-34A8-42AA-A1E1-4828BB8F8AEA Q50002313-8361F7DE-0135-43C7-8700-4EE47F8D509F Q53098976-8C64D3BE-B578-4FF5-BA19-08F0D656067E Q54978927-EB8E6D35-F21F-44A6-BCAE-A8936BE0A1A3 Q58761668-216069BA-AB0D-49A3-9E23-90BC524E8427

P2860

Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study).

http://www.wikidata.org/entity/Q34092442

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Clinical efficacy, radiographi ...... d trial (the GO-REVEAL study).

@ast

Clinical efficacy, radiographi ...... d trial (the GO-REVEAL study).

@en

Clinical efficacy, radiographi ...... d trial (the GO-REVEAL study).

@nl

type

label

Clinical efficacy, radiographi ...... d trial (the GO-REVEAL study).

@ast

Clinical efficacy, radiographi ...... d trial (the GO-REVEAL study).

@en

Clinical efficacy, radiographi ...... d trial (the GO-REVEAL study).

@nl

prefLabel

Clinical efficacy, radiographi ...... d trial (the GO-REVEAL study).

@ast

Clinical efficacy, radiographi ...... d trial (the GO-REVEAL study).

@en

Clinical efficacy, radiographi ...... d trial (the GO-REVEAL study).

@nl

P1433

Q34092442-13C4CADF-9E3B-4682-9F65-41991AE6C81C

P1476

Q34092442-0777C4D8-B578-4F45-A56F-6CE948F40FC5

P2093

Q34092442-408CD8D2-DC74-4350-8BAB-F11FE1890F53

Q34092442-4B01DDEA-977E-4F6C-871D-33B5BBEB5B0C

Q34092442-8DD0D66F-83CC-4ABB-9DBF-5ECC13C47758

Q34092442-B0C6DBBF-0A0A-4375-B5D2-97700F265A02

Q34092442-B1A72CEA-7EF5-421E-BBA0-5703084CBDE6

Q34092442-C23FE18C-F40A-463A-AC1B-2BD9DAF9690C

Q34092442-D15F47A7-DB17-44B2-BADF-B82ED1FC7091

Q34092442-DDBCF4B2-03A7-4C4C-9DED-009222B76720

P2860

Q34092442-13B16013-CDB8-4330-A287-0D92A3E8BF54

Q34092442-3624FC81-B746-4EE6-8368-B337093FC2CA

Q34092442-5C682756-58E9-47B5-ACF7-0C6C66E4730C

Q34092442-61F56E7F-74A9-433C-B2E9-4694D200BBE2

Q34092442-9F8422C4-2719-4D3E-B40F-0B673E45DFAD

P304

Q34092442-C5E6F553-0ECF-4B27-A616-3C88EE1792A9

P31

Q34092442-BFC2F526-0CB4-42DC-83EF-91A0BA2AACAA

P356

Q34092442-A556B0CE-0CF2-4553-BC55-767A4795FB73

P407

Q34092442-2F9575C6-731F-43F0-A391-36E4065062E2

P433

Q34092442-FCFD2AB1-17B4-48E1-B543-F6D964F8C61B

P478

Q34092442-2F20E2CD-FACC-45BD-B2B4-8D10F56126E8

P50

Q34092442-321C2143-628D-4520-9A02-9C373C8089ED

Q34092442-38FDBFB9-1872-416E-94E3-F36186A1301A

Q34092442-C38D202B-A09F-4E67-BBE8-DBA3ADC4D988

P577

Q34092442-61250FF6-9573-4942-8807-5554F8AB6D17

P698

Q34092442-2850731A-E252-4655-A5A1-B598932E09CA

P921

Q34092442-38F6BC44-0579-458A-88C6-3DD6CC089DB9

P932

Q34092442-9F41D3B3-BB76-4D68-8FD1-F67EB198BBF6

P356

ANNRHEUMDIS-2013-204902

P1433

Annals of the Rheumatic Diseases

P1476

Clinical efficacy, radiographi ...... d trial (the GO-REVEAL study).

@en

P2093

Anna Beutler

http://www.w3.org/2001/XMLSchema#string

Arthur Kavanaugh

http://www.w3.org/2001/XMLSchema#string

Gerald G Krueger

http://www.w3.org/2001/XMLSchema#string

Jiandong Lu

http://www.w3.org/2001/XMLSchema#string

Jocelyn H Leu

http://www.w3.org/2001/XMLSchema#string

Neil Goldstein

http://www.w3.org/2001/XMLSchema#string

Philip Mease

http://www.w3.org/2001/XMLSchema#string

Yiying Zhou

http://www.w3.org/2001/XMLSchema#string

P2860

Gastroesophageal Reflux Disease (GERD)

Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study.

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.

Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial.

Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT).

P304

1689-1694

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ANNRHEUMDIS-2013-204902

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P50

Dafna D. Gladman

Désirée van der Heijde

P577

2014-04-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24748630

http://www.w3.org/2001/XMLSchema#string

P921

P932

4145441

http://www.w3.org/2001/XMLSchema#string